These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

506 related items for PubMed ID: 33429932

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Differential Sensitivity of the Protein Translation Initiation Machinery and mTOR Signaling to MECP2 Gain- and Loss-of-Function Involves MeCP2 Isoform-Specific Homeostasis in the Brain.
    Buist M, El Tobgy N, Shevkoplyas D, Genung M, Sher AA, Pejhan S, Rastegar M.
    Cells; 2022 Apr 24; 11(9):. PubMed ID: 35563748
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. MeCP2 binds to non-CG methylated DNA as neurons mature, influencing transcription and the timing of onset for Rett syndrome.
    Chen L, Chen K, Lavery LA, Baker SA, Shaw CA, Li W, Zoghbi HY.
    Proc Natl Acad Sci U S A; 2015 Apr 28; 112(17):5509-14. PubMed ID: 25870282
    [Abstract] [Full Text] [Related]

  • 9. Rett syndrome and MeCP2.
    Liyanage VR, Rastegar M.
    Neuromolecular Med; 2014 Jun 28; 16(2):231-64. PubMed ID: 24615633
    [Abstract] [Full Text] [Related]

  • 10. Novel alterations in the epigenetic signature of MeCP2-targeted promoters in lymphocytes of Rett syndrome patients.
    Lilja T, Wallenborg K, Björkman K, Albåge M, Eriksson M, Lagercrantz H, Rohdin M, Hermanson O.
    Epigenetics; 2013 Mar 28; 8(3):246-51. PubMed ID: 23348913
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. PTP1B inhibition suggests a therapeutic strategy for Rett syndrome.
    Krishnan N, Krishnan K, Connors CR, Choy MS, Page R, Peti W, Van Aelst L, Shea SD, Tonks NK.
    J Clin Invest; 2015 Aug 03; 125(8):3163-77. PubMed ID: 26214522
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. MECP2 Mutations in the Rett Syndrome Patients from South India.
    Anitha A, Poovathinal SA, Viswambharan V, Thanseem I, Iype M, Anoop U, Sumitha PS, Parakkal R, Vasu MM.
    Neurol India; 2022 Aug 03; 70(1):249-253. PubMed ID: 35263890
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Early intervention with psychostimulants or antidepressants to increase methyl-CpG-binding protein 2 (MeCP2) expressions: a potential therapy for Rett syndrome.
    Pan CH, Tsai S.
    Med Sci Monit; 2012 Jan 03; 18(1):HY1-3. PubMed ID: 22207122
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.